Iron-Replete Hemodialysis Patients Do Not Require Higher EPO Dosages When Converting From Subcutaneous to Intravenous Administration: Results of the Italian Study on Erythropoietin Converting (ISEC)

American Journal of Kidney Diseases

Volumn 47, Issue 6, 2006, Pages 1027-1035

  Pizzarelli, Francesco ^a,b,c,d   David, Salvatore ^a,b,c,d   Sala, Patrizio ^a,b,c,d   Icardi, Andrea ^a,b,c,d   Casani, Aldo ^a,b,c,d  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b Parma Hospital   (Italy)

^c Arenzano Hospital ^*

^d Massa Hosp   (Italy)

Author keywords

Anemia; erythropoietin; hemodialysis (HD); intravenous; subcutaneous

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; DOSE RESPONSE; FEMALE; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; IRON STORAGE; ITALY; MAJOR CLINICAL STUDY; MALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IRON; ITALY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; REGRESSION ANALYSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33646778529     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.02.176     Document Type: Article

References (28)

1. Steffensen G., Aunsholt N.A., and Ahlbom G. Comparative crossover study of intravenously and subcutaneously administered recombinant human erythropoietin in hemodialysis patients. Blood Purif 10 (1992) 241-247
2. Albitar S., Meulders Q., Hammoud H., Soutif C., Bouvier P., and Pollini J. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 10 suppl 6 (1995) S40-S43
3. Jensen J.D., Madsen J.K., and Jensen L.W. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. Eur J Clin Pharmacol 50 (1996) 171-177
4. Virot J.S., Janin G., Guillaumie J., et al. Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient?. Am J Kidney Dis 28 (1996) 400-408
5. Bommer J., Samtleben W., Koch K.M., Baldamus C.A., Grutzmacher P., and Scigalla P. Variations of recombinant human erythropoietin application in hemodialysis patients. Contrib Nephrol 76 (1989) 149-158
6. Bommer J., Barth H.-P., Zeier M., et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 88 (1991) 136-143
7. Besarab A., Flaharty K.K., Erslev A.J., et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease. The case for subcutaneous administration. J Am Soc Nephrol 2 (1992) 1405-1416
8. Muirhead N., Churchill D.N., Goldstein M., et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 12 (1992) 303-310
9. Morsli R., Moriniere P., El Esper N., et al. Comparison of s.c. and i.v. rHuEpo in patients on chronic hemodialysis. Comparable correction of anaemia with lower doses because of greater bioavailability. Nephrol Dial Transplant 8 (1993) 961A (abstr)
10. Pelegri A., Roca R., Rodriguez J.A., et al. Valuation upon the route of administration of rHuEPO in hemodialysis patients (HP). Kidney Int 44 (1993) 1430A (abstr)
11. Boran M., Dalva I., Yazicioglu A., and Çetin S. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients. Nephron 63 (1993) 113-114
12. Bovy C., Dubois B., Popovic A., Saint-Remy A., and Rorive G. Mode of administration of erythropoietin (rHuEPO). Does it matter?. Nephrol Dial Transplant 10 (1995) 1951-1952
13. Paganini E.P., Eschbach J.W., Lazarus J.M., et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis 26 (1995) 331-340
14. Parker K.P., Mitch W.E., Stivelman J.C., Macon E.J., Bailey J.L., and Sands J.M. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol 8 (1997) 288-293
15. Balkovetz D.F., Frazier C., and Sanders P.W. Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit. Nephrol Dial Transplant 13 (1998) 2979-2980
16. Besarab A., Reyes C.M., and Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (2002) 439-446
17. Kaufman J.S., Reda D.J., Fye C.L., et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339 (1998) 578-583
18. McClellan W.M., Frankenfield D.L., Wish J.B., Rocco M.V., Johnson C.A., and Owen W.F. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients. Results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis 37 (2001) E36
19. Jacobs C., Frei D., and Perkins A.C. Results of the European Survey on Anaemia Management 2003 (ESAM 2003). Current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 20 suppl 3 (2005) Siii3-Siii24
20. De Schoenmakere G., Lameire N., Dhondt A., et al. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant 13 (1998) 1770-1775
21. Fullerton L., Bhattacharjee D., Roe S.D., and Cassidy M.J.D. Erythropoietin. Subcutaneous or intravenous dosing?. Br J Ren Med 7 (2002) 17-19
22. Leikis M.J., Kent A.B., Becker G.J., and McMahon L.P. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients. Nephrology 9 (2004) 153-160
23. Taylor J.E., Peat N., Porter C., and Morgan A.G. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11 (1996) 1079-1083
24. European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure: Target guideline 5: Target haemoglobin concentration for the treatment of the anaemia of chronic renal failure. Nephrol Dial Transplant 14 suppl 5 (1999) S11-S13
25. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease. Update 2000. Am J Kidney Dis 37 suppl 1 (2001) S182-S238
26. Zingraff J., Drüeke T., and Marie P. Anemia and secondary hyperparathyroidism. Arch Intern Med 138 (1978) 1650-1652
27. Rao D.S., Shih M.S., and Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328 (1993) 171-175
28. Locatelli F., Pisoni R.L., Combe C., et al. Anaemia in haemodialysis patients of five European countries. Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (2004) 121-132